SIX · WKBN.SW
Walliser Kantonalbank
CHF 166.50+CHF 0.50 (+0.3%)
Walliser Kantonalbank’s quoted price sits in the upper half of its reported 52-week range, 1.77% below the high.
Loading market information…
SIX · HBMN.SW · CHF
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
HBM Healthcare Investments AG’s quoted price sits in the lower half of its reported 52-week range, 13.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
HBM Healthcare Investments AG’s forward annual dividend is CHF 9.00 per share, paid annual. The forward yield is 4.02% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
HBM Healthcare Investments AG’s next earnings report is currently expected on Jan 22, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow HBM Healthcare Investments AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HBM Healthcare Investments AG specializes in both direct investments and a fund-of-funds strategy, focusing exclusively on the healthcare sector, encompassing human medicine, pharmaceuticals, biotechnology, diagnostics, and medical technology. Its direct investments target a diverse range of companies, from early-stage startups and various venture and growth phases to mature private enterprises, unlisted emerging firms, and small-cap public entities. The firm also provides capital for company buyouts, growth initiatives, Private Investments in Public Equity (PIPEs), and the spin-off of product lines or departments from larger corporations, as well as the expansion or restructuring of established businesses. Through its fund-of-funds approach, HBM allocates capital to venture capital funds. Initial direct investments are typically made in companies whose primary products are either in clinical development or just prior to that stage. With a global investment mandate, the company emphasizes opportunities in North America, Europe, and the Asia Pacific region. For publicly traded companies, HBM generally prioritizes those that originated within its private investment portfolio. The firm often increases its commitment to portfolio companies through subsequent financing rounds or after their initial public offering. HBM frequently secures a seat on the portfolio company's Board of Directors and may acquire majority stakes. While primarily investing through equity, it also employs various other financial instruments, including convertible bonds, debt securities, structured products, and derivatives. Exits from these investments are typically facilitated through trade sales or initial public offerings.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:25 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| -CHF 47.01M |
| Q3 2024 | Jan 20, 2025 | CHF 6.47 | CHF 44.80M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 166.50+CHF 0.50 (+0.3%)
Walliser Kantonalbank’s quoted price sits in the upper half of its reported 52-week range, 1.77% below the high.
CHF 34.70-CHF 0.10 (-0.29%)
Banque Cantonale de Genève S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.47% below the high.
CHF 145.00-CHF 1.00 (-0.68%)
Valiant Holding AG’s quoted price sits in the lower half of its reported 52-week range, 21.37% below the high.
CHF 732.00-CHF 9.00 (-1.21%)
Vaudoise Assurances Holding S.A.’s quoted price sits in the lower half of its reported 52-week range, 13.88% below the high.
CHF 2,590.00+CHF 40.00 (+1.57%)
Graubündner Kantonalbank’s quoted price sits in the upper half of its reported 52-week range, 7.83% below the high.
CHF 161.00CHF 0.00 (0.0%)
Thurgauer Kantonalbank’s quoted price sits in the lower half of its reported 52-week range, 17.01% below the high.
CHF 93.10-CHF 0.30 (-0.32%)
VP Bank AG’s quoted price sits in the upper half of its reported 52-week range, 5.1% below the high.
CHF 58.80CHF 0.00 (0.0%)
Private Equity Holding AG’s quoted price sits in the lower half of its reported 52-week range, 10.09% below the high.
